Clinical Trial Update: Lenvatinib and Pembrolizumab in Resectable Mucosal Melanoma [Phase 2]

View source ↗

Summary

Phase 2 trial update of lenvatinib plus pembrolizumab for neoadjuvant treatment in resectable mucosal melanoma.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Mucosal Melanoma

Drugs mentioned

• Lenvatinib (lenvatinib)
• Pembrolizumab (pembrolizumab)

Snippet

Sponsor: Peking University Cancer Hospital & Institute | Conditions: Mucosal Melanoma, Neoadjuvant Treatment | Phase 2 | Status: UNKNOWN